Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00469222
Other study ID # LU-11-0072 / 23117
Secondary ID
Status Completed
Phase Phase 1
First received May 2, 2007
Last updated February 24, 2016
Start date March 2007
Est. completion date April 2011

Study information

Verified date March 2012
Source AHS Cancer Control Alberta
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

Current treatments for limited stage small cell lung cancer have poor cure rates. The addition of chest radiation to chemotherapy improves cure rates, but these cancers still come back in the chest 30-50% of the time. Two factors which can improve control and cure rates for this cancer are increasing the chest radiation dose and minimizing the overall time it takes to complete radiation treatments. One method to achieve both of these goals is to give more radiation each day. This study is meant to study how tolerable and effective it would be to increase the intensity of chest radiation for small cell lung cancer patients by increasing the daily radiation dose. We aim to find the highest dose of chest radiotherapy that can be safely given with chemotherapy using this strategy. Patients in this trial will be monitored before, during and after their radiation and chemotherapy treatments for treatment side-effects, how effective treatments are at controlling their cancer and quality of life changes. Results from this trial will help to define more effective radiotherapy doses which are tolerable for this type of lung cancer and the quality of life changes patients experience when they undergo these treatments.


Description:

Local control and overall survival rates associated with the standard chemotherapy and radiotherapy given for limited stage small cell lung cancer are poor and emerging evidence from several studies suggests that intensifying the radiotherapy dose given may further improve patient outcomes, but at the cost of increased radiotherapy side effects. This proposal aims to study a novel method of intensifying chest radiotherapy dose via increasing the daily radiotherapy dose which is directed at regions of visible disease only. This strategy allows for delivery of increased radiation doses without prolonging overall treatment time and allowing potential regrowth of cancer cells. We aim to determine the maximum radiation dose which can be safely given with chemotherapy for limited stage small cell lung cancer and study the effects this type of radiation regimen with chemotherapy has on patient side effects and quality of life. Results from this trial will contribute to the development of the ideal radiotherapy regimen for limited stage small cell lung cancer. Our results will add to the literature studying the effects dose-intense radiation strategies for lung cancer have on patient quality of life.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date April 2011
Est. primary completion date April 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- patients with histologically or cytologically proven newly diagnosed small cell lung cancer

- confirmation from the treating radiation oncologist that the patient has limited stage disease (i.e. disease that can be encompassed by radiotherapy portals without exposing patient to excessive risk of radiation lung injury)

- adequate pulmonary function tests (FEV-1 >1.0, DLCO >50%)

- patients of childbearing potential must practice adequate contraception

- age greater than 18 years

- Karnofsky performance status greater than 70

- adequate hematologic, hepatic and renal function: Hb>100g/L, WBC > 4.0x109/L, neutrophils > 1.0x109/L, platelets > 100,000x109/L, calculated GFR based on Cockcroft-Gault formula of >60mL/min (NOTE: for cisplatin, GFR must be above 60ml/min; if less than 60ml/min the patient can not receive cisplatin but could be considered for carboplatin)

- patients must sign a study specific informed consent form

Exclusion Criteria:

- patient who have undergone complete or subtotal tumour resection

- evidence of non-small cell histology

- pericardial or pleural effusion on radiologic investigations regardless of cytology

- patients cannot be treated with 3DCRT with adherence to the dose volume constraints

- prior or concurrent malignancy except non-melanomatous skin cancer unless disease-free for at least 5 years

- prior radiotherapy to the thorax or neck

- prior chemotherapy

- patients with myocardial infarction within the preceding 6 months or symptomatic heart disease, including angina, congestive heart failure, uncontrolled arrhythmias

- compromised lung function with inadequate pulmonary function tests (FEV-1<1.0, DLCO <50%)

- pregnancy (patients with childbearing potential must practice appropriate contraception)

- patients who have not had the pre-treatment evaluations outlined in the protocol

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Procedure:
hypofractionated external beam


Locations

Country Name City State
Canada Cross Cancer Institute Edmonton Alberta

Sponsors (2)

Lead Sponsor Collaborator
AHS Cancer Control Alberta Cross Cancer Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rates of acute grade 3 or higher radiotherapy toxicities
Secondary Overall survival and disease free survival, patient related quality of life
See also
  Status Clinical Trial Phase
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Completed NCT04508270 - Significance of Early Mobilization After VATS-L
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Completed NCT05469425 - Home-based Preoperative Exercise Training for Lung Cancer Patients Undergoing Surgery N/A
Recruiting NCT05046067 - Feasibility Study of Anatomical Modeling for Image Guided Thoracic Surgery N/A
Terminated NCT03090880 - Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE) Phase 3
Recruiting NCT05596760 - Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers N/A
Completed NCT02498860 - Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung Phase 2
Completed NCT02952261 - Application of 3D Printing Technique in Small Pulmonary Nodule Localization N/A
Not yet recruiting NCT06024538 - Role of Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays in the Resistance of Non-small Cell Lung Cancer to Anti-PD1/PD-L1 Therapies
Recruiting NCT02965300 - The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis N/A
Completed NCT02616211 - An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
Recruiting NCT00765986 - Pilot Study of 18F-FAZA in Assessing Early Functional Response in Patients With Inoperable Non Small Cell Lung Cancer Undergoing Radiotherapy or Chemo-radiotherapy N/A
Completed NCT03320044 - Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
Recruiting NCT03655015 - Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Completed NCT03741868 - Symptom Burden and Unmet Supportive Care Needs in Lung Cancer Patients Undergoing First or Second Line Immunotherapy
Not yet recruiting NCT05179408 - Telerehabilitation Following Lung Cancer N/A
Completed NCT03749512 - NLCR in Prediction of the Grade of Lung Tumor.
Recruiting NCT03664843 - Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients
Completed NCT01261507 - Reader Study of DeltaView™ Chest Radiograph Software N/A